Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-05-24 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction of shares held by a significant shareholder (鼎泰海富投资管理有限公司) in the company 上海泓博智源医药股份有限公司. The document includes specifics about the shareholding before and after the change, the method of reduction (concentrated bidding), dates, and legal compliance statements. It references relevant securities laws and disclosure requirements. There is no indication that this is a full annual or interim report, audit report, or earnings release. Instead, it is a formal notification of a change in major shareholding, specifically a reduction below the 5% threshold. This fits the definition of a Major Shareholding Notification (MRQ). The document length (5407 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing fallback. Therefore, the filing type is MRQ with high confidence.
2024-05-24 Chinese
关于持股5%以上股东减持至5%以下暨权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholder's reduction of holdings from above 5% to below 5%, including detailed shareholding changes and compliance with relevant securities laws and regulations. It references a '简式权益变动报告书' (Simplified Equity Change Report) and provides specifics on share quantities and percentages before and after the change. This type of document is a notification of a major shareholding change, not a full financial report or earnings release. It fits the definition of a Major Shareholding Notification (MRQ). The document length is 2057 characters, which is typical for such announcements and not a full report. Therefore, the correct classification is MRQ with high confidence.
2024-05-24 Chinese
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of the shareholder votes on various resolutions. The document does not contain the actual annual report or financial statements but rather provides a legal opinion on the AGM process and the validity of the voting results. The document length is 3646 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full annual report. Therefore, this document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2024-05-15 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the resolutions passed at the 2023 Annual General Meeting (AGM), including approval of the 2023 annual report, board work report, supervisory board report, financial statements, profit distribution plan, and other corporate governance matters. The document includes voting results, meeting attendance, and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports on the voting outcomes and decisions made at the AGM. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4895 characters, which is sufficient to include detailed voting results and meeting information, not just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2024-05-15 Chinese
关于举行2023年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding a 2023 annual online earnings explanation meeting (业绩说明会) scheduled for May 17, 2024. It references the 2023 Annual Report already disclosed on April 24, 2024, and invites investors to participate and submit questions. The document does not contain actual financial statements or detailed financial data but is an invitation and notice for an investor presentation event related to the annual results. Therefore, it is best classified as an Investor Presentation (IP) announcement rather than the Annual Report (10-K) itself or an Earnings Release (ER). The document length is short and focused on the event notice and investor interaction.
2024-05-10 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2023年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度跟踪报告" (2023 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 上海泓博智源医药股份有限公司 (Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.). It details the sponsor's review and supervision work, including information disclosure, internal control, fundraising supervision, governance, and regulatory compliance issues during the year 2023. The document includes detailed descriptions of regulatory measures, internal audits, and compliance with securities regulations. It is a comprehensive report on the sponsor's ongoing monitoring and oversight activities rather than a full annual report or financial statement. This type of document aligns with the category of Audit Report / Information (AR), as it is a standalone report focusing on audit, compliance, and regulatory oversight rather than a full annual report (10-K) or other categories. The document length (9500 characters) and content confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-05-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.